Demographic Characteristics of Study Participants (According-to-Protocol Cohorts for Immunogenicity)
| . | Cohort for Humoral Immunogenicity . | Cohort for Cell-Mediated Immunogenicity . | ||
|---|---|---|---|---|
| HZ/su (N = 1457) . | Placebo (N = 1479) . | HZ/su (N = 212) . | Placebo (N = 218) . | |
| Age (years) . | ||||
| Mean age at vaccine dose 1, years ± SD | 67.5 ± 9.5 | 67.8 ± 9.5 | 64.1 ± 9.0 | 64.5 ± 8.9 |
| 50–59, n (%) | 356 (24.4) | 355 (24.0) | 74 (34.9) | 73 (33.5) |
| 60–69, n (%) | 359 (24.6) | 356 (24.1) | 68 (32.1) | 72 (33.0) |
| ≥70, n (%) | 70 (33.0) | 73 (33.5) | ||
| 70–79, n (%) | 597 (41.0) | 608 (41.1) | ||
| ≥80, n (%) | 145 (10.0) | 160 (10.8) | ||
| Sex, n (%) | ||||
| Female | 852 (58.5) | 864 (58.4) | 108 (50.9) | 119 (54.6) |
| Male | 605 (41.5) | 615 (41.6) | 104 (49.1) | 99 (45.4) |
| Geographic ancestry, n (%) | ||||
| White–Caucasian/European | 1010 (69.3) | 1032 (69.8) | 122 (57.5) | 128 (58.7) |
| Asian–East Asian | 250 (17.2) | 245 (16.6) | 1 (0.5) | 0 (0.0) |
| Asian–Japanese Heritage | 126 (8.6) | 128 (8.7) | 72 (34.0) | 75 (34.4) |
| African/African American | 31 (2.1) | 25 (1.7) | 17 (8.0) | 14 (6.4) |
| Other | 40 (2.8) | 49 (3.3) | 0 (0.0) | 1 (0.5) |
| . | Cohort for Humoral Immunogenicity . | Cohort for Cell-Mediated Immunogenicity . | ||
|---|---|---|---|---|
| HZ/su (N = 1457) . | Placebo (N = 1479) . | HZ/su (N = 212) . | Placebo (N = 218) . | |
| Age (years) . | ||||
| Mean age at vaccine dose 1, years ± SD | 67.5 ± 9.5 | 67.8 ± 9.5 | 64.1 ± 9.0 | 64.5 ± 8.9 |
| 50–59, n (%) | 356 (24.4) | 355 (24.0) | 74 (34.9) | 73 (33.5) |
| 60–69, n (%) | 359 (24.6) | 356 (24.1) | 68 (32.1) | 72 (33.0) |
| ≥70, n (%) | 70 (33.0) | 73 (33.5) | ||
| 70–79, n (%) | 597 (41.0) | 608 (41.1) | ||
| ≥80, n (%) | 145 (10.0) | 160 (10.8) | ||
| Sex, n (%) | ||||
| Female | 852 (58.5) | 864 (58.4) | 108 (50.9) | 119 (54.6) |
| Male | 605 (41.5) | 615 (41.6) | 104 (49.1) | 99 (45.4) |
| Geographic ancestry, n (%) | ||||
| White–Caucasian/European | 1010 (69.3) | 1032 (69.8) | 122 (57.5) | 128 (58.7) |
| Asian–East Asian | 250 (17.2) | 245 (16.6) | 1 (0.5) | 0 (0.0) |
| Asian–Japanese Heritage | 126 (8.6) | 128 (8.7) | 72 (34.0) | 75 (34.4) |
| African/African American | 31 (2.1) | 25 (1.7) | 17 (8.0) | 14 (6.4) |
| Other | 40 (2.8) | 49 (3.3) | 0 (0.0) | 1 (0.5) |
Abbreviations: HZ/su, herpes zoster subunit vaccine; N, number of participants in the group; n (%), number and percentage of participants in a given category; SD, standard deviation.
Demographic Characteristics of Study Participants (According-to-Protocol Cohorts for Immunogenicity)
| . | Cohort for Humoral Immunogenicity . | Cohort for Cell-Mediated Immunogenicity . | ||
|---|---|---|---|---|
| HZ/su (N = 1457) . | Placebo (N = 1479) . | HZ/su (N = 212) . | Placebo (N = 218) . | |
| Age (years) . | ||||
| Mean age at vaccine dose 1, years ± SD | 67.5 ± 9.5 | 67.8 ± 9.5 | 64.1 ± 9.0 | 64.5 ± 8.9 |
| 50–59, n (%) | 356 (24.4) | 355 (24.0) | 74 (34.9) | 73 (33.5) |
| 60–69, n (%) | 359 (24.6) | 356 (24.1) | 68 (32.1) | 72 (33.0) |
| ≥70, n (%) | 70 (33.0) | 73 (33.5) | ||
| 70–79, n (%) | 597 (41.0) | 608 (41.1) | ||
| ≥80, n (%) | 145 (10.0) | 160 (10.8) | ||
| Sex, n (%) | ||||
| Female | 852 (58.5) | 864 (58.4) | 108 (50.9) | 119 (54.6) |
| Male | 605 (41.5) | 615 (41.6) | 104 (49.1) | 99 (45.4) |
| Geographic ancestry, n (%) | ||||
| White–Caucasian/European | 1010 (69.3) | 1032 (69.8) | 122 (57.5) | 128 (58.7) |
| Asian–East Asian | 250 (17.2) | 245 (16.6) | 1 (0.5) | 0 (0.0) |
| Asian–Japanese Heritage | 126 (8.6) | 128 (8.7) | 72 (34.0) | 75 (34.4) |
| African/African American | 31 (2.1) | 25 (1.7) | 17 (8.0) | 14 (6.4) |
| Other | 40 (2.8) | 49 (3.3) | 0 (0.0) | 1 (0.5) |
| . | Cohort for Humoral Immunogenicity . | Cohort for Cell-Mediated Immunogenicity . | ||
|---|---|---|---|---|
| HZ/su (N = 1457) . | Placebo (N = 1479) . | HZ/su (N = 212) . | Placebo (N = 218) . | |
| Age (years) . | ||||
| Mean age at vaccine dose 1, years ± SD | 67.5 ± 9.5 | 67.8 ± 9.5 | 64.1 ± 9.0 | 64.5 ± 8.9 |
| 50–59, n (%) | 356 (24.4) | 355 (24.0) | 74 (34.9) | 73 (33.5) |
| 60–69, n (%) | 359 (24.6) | 356 (24.1) | 68 (32.1) | 72 (33.0) |
| ≥70, n (%) | 70 (33.0) | 73 (33.5) | ||
| 70–79, n (%) | 597 (41.0) | 608 (41.1) | ||
| ≥80, n (%) | 145 (10.0) | 160 (10.8) | ||
| Sex, n (%) | ||||
| Female | 852 (58.5) | 864 (58.4) | 108 (50.9) | 119 (54.6) |
| Male | 605 (41.5) | 615 (41.6) | 104 (49.1) | 99 (45.4) |
| Geographic ancestry, n (%) | ||||
| White–Caucasian/European | 1010 (69.3) | 1032 (69.8) | 122 (57.5) | 128 (58.7) |
| Asian–East Asian | 250 (17.2) | 245 (16.6) | 1 (0.5) | 0 (0.0) |
| Asian–Japanese Heritage | 126 (8.6) | 128 (8.7) | 72 (34.0) | 75 (34.4) |
| African/African American | 31 (2.1) | 25 (1.7) | 17 (8.0) | 14 (6.4) |
| Other | 40 (2.8) | 49 (3.3) | 0 (0.0) | 1 (0.5) |
Abbreviations: HZ/su, herpes zoster subunit vaccine; N, number of participants in the group; n (%), number and percentage of participants in a given category; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
